Samsung C&T commits $687M to Samsung Biologics' $2B rights offering
What's the deal? Samsung C&TDealroom has a profile for this one. Try Dealroom → will invest US$770.5M (≈$687 million) in a rights offering by affiliate Samsung BiologicsDealroom has a profile for this one. Try Dealroom →, acquiring 782,818 common shares. The commitment, resolved by its board on October 28, lifts Samsung C&T's total investment in the biologics firm to US$2.58B.
What's the endgame? The investment is part of Samsung Biologics' larger US$2.52B rights offering. The company plans to allocate roughly US$2.27B toward acquiring Swiss peptide contract development and manufacturing organization (CDMO) PolyPeptide GroupDealroom has a profile for this one. Try Dealroom →, with the balance funding expansion of its Songdo campus.
Why now? The deal would push Samsung Biologics beyond its antibody-focused manufacturing into peptides, including ingredients used in obesity and diabetes drugs. The subscription period for existing shareholders closes November 10.
Samsung C&T framed the move as backing "a mid- to long-term growth driver."
What could go wrong? The offering drew a skeptical market response, with shares falling sharply on announcement as investors questioned the choice of equity funding over debt and whether the acquisition will deliver returns. Analysts have called the move "very disappointing" for relying solely on a rights offering, warning the company must prove its multi-trillion-won capital expenditure plan step by step.
The signal: At roughly $687 million, Samsung C&T's contribution ranks in the 96th percentile of post-IPO equity rounds across the region over the trailing 48 months. It marks a decisive vote of support from a key Samsung affiliate — but the strategic rationale and execution, not the funding alone, remain the test.
Read more: en.infomaxai.com
Image credit: Generated with Gemini
